Who is sponsoring NCT00392535?

NCT00392535 is sponsored by Institute of Cancer Research, United Kingdom.

What drugs are being tested in NCT00392535?

Interventions in NCT00392535: conventional radiotherapy 74 Gy delivered in 37 fractions, hypofractionated radiation therapy 60 Gy in 20 fractions, hypofractionated radiation therapy 57 Gy in 19 fractions.

What condition does NCT00392535 study?

NCT00392535 studies Prostate Cancer.

Is NCT00392535 still recruiting?

NCT00392535 is currently status unknown. Last updated 27 February 2019.

Last reviewed 2019-02-27 · How we verify

NCT00392535

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer

Status unknown NA Last updated 27 February 2019

What this trial tests

NA trial testing conventional radiotherapy 74 Gy delivered in 37 fractions in Prostate Cancer in 3,216 participants. Status unknown.

Timeline

18 October 2002

Primary endpoint
8 September 2015

17 June 2021

Quick facts

Lead sponsor	Institute of Cancer Research, United Kingdom
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Primary purpose	treatment
Enrollment	3,216
Start date	18 October 2002
Primary completion	8 September 2015
Estimated completion	17 June 2021
Sites	26 locations across United Kingdom

Drugs / interventions tested

conventional radiotherapy 74 Gy delivered in 37 fractions
hypofractionated radiation therapy 60 Gy in 20 fractions
hypofractionated radiation therapy 57 Gy in 19 fractions

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Institute of Cancer Research, United Kingdom

Who can join

Adults 18 to 120, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet known which schedule of intensity-modulated radiation therapy is more effective in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying the side effects of three schedules of intensity-modulated radiation therapy and compares how well they work in treating patients with localized prostate cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Systematic review of hypofractionated radiation therapy for prostate cancer.
Zaorsky NG, Ohri N, Showalter TN, Dicker AP, et al · · 2013 · cited 42× · PMID 23453861 · DOI 10.1016/j.ctrv.2013.01.008
Improving radiotherapy quality assurance in clinical trials: assessment of target volume delineation of the pre-accrual benchmark case.
Gwynne S, Spezi E, Sebag-Montefiore D, Mukherjee S, et al · · 2013 · cited 39× · PMID 23392188 · DOI 10.1259/bjr.20120398
Hypofractionation for clinically localized prostate cancer.
Hickey BE, James ML, Daly T, Soh FY, et al · · 2019 · cited 34× · PMID 31476800 · DOI 10.1002/14651858.cd011462.pub2

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Institute of Cancer Research, United Kingdom trials

Trials by the same sponsor.

NCT06396754 — Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC · not yet recruiting
NCT07391215 — 5G-PEARL: Paxalisib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting
NCT07098819 — The eValuation of Sources of vIBRAtioN for Vibrational Shear Wave elasTography · not yet recruiting
NCT06636526 — The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study). · recruiting
NCT06630260 — 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00392535 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Cancer Research, United Kingdom
Last refreshed: 27 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00392535.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing